Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1295505.RACG0Fa2ejRcp4DLkUKq4T7e9chSavHrFwXJy7_UiAvRw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1295505.RACG0Fa2ejRcp4DLkUKq4T7e9chSavHrFwXJy7_UiAvRw130_assertion type Assertion NP1295505.RACG0Fa2ejRcp4DLkUKq4T7e9chSavHrFwXJy7_UiAvRw130_head.
- NP1295505.RACG0Fa2ejRcp4DLkUKq4T7e9chSavHrFwXJy7_UiAvRw130_assertion description "[Specific inhibitors against BCR-ABL, such as Imatinib mesylate (IM), have greatly improved CML management; however, no single agent is a cure yet.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1295505.RACG0Fa2ejRcp4DLkUKq4T7e9chSavHrFwXJy7_UiAvRw130_provenance.
- NP1295505.RACG0Fa2ejRcp4DLkUKq4T7e9chSavHrFwXJy7_UiAvRw130_assertion evidence source_evidence_literature NP1295505.RACG0Fa2ejRcp4DLkUKq4T7e9chSavHrFwXJy7_UiAvRw130_provenance.
- NP1295505.RACG0Fa2ejRcp4DLkUKq4T7e9chSavHrFwXJy7_UiAvRw130_assertion SIO_000772 26554155 NP1295505.RACG0Fa2ejRcp4DLkUKq4T7e9chSavHrFwXJy7_UiAvRw130_provenance.
- NP1295505.RACG0Fa2ejRcp4DLkUKq4T7e9chSavHrFwXJy7_UiAvRw130_assertion wasDerivedFrom befree-2016 NP1295505.RACG0Fa2ejRcp4DLkUKq4T7e9chSavHrFwXJy7_UiAvRw130_provenance.
- NP1295505.RACG0Fa2ejRcp4DLkUKq4T7e9chSavHrFwXJy7_UiAvRw130_assertion wasGeneratedBy ECO_0000203 NP1295505.RACG0Fa2ejRcp4DLkUKq4T7e9chSavHrFwXJy7_UiAvRw130_provenance.